Adcock Ingram Holdings Ltd.
http://www.adcock.co.za
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adcock Ingram Holdings Ltd.
Blitzima A Boost For Adcock As It Scoops Up New Rituximab Patients
South Africa’s Adcock Ingram gave a sprawling update of its operations for the first half of its financial year ending in June 2022, which saw a rise in sales but a decline in profit for its Prescription business.
Adcock Ingram Breaks Into Biosimilars With Infliximab
South African firm Adcock Ingram has described the launch of Celltrion’s Remsima (infliximab) biosimilar as “a really good step for us,” as it saw volumes plunge for its Prescription business during its financial year ended 30 June.
Adcock Reports Slight Growth In A ‘Difficult Market’
Adcock has made slight progress despite the effect of the current economic climate in South Africa on consumer spending and behavior.
Deals Shaping The Medical Industry, July/August 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer